Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Feels like targeted, timed buying ahead of meaningful data/news. That being said, I've been wrong so much on this stock that I predict a complete nothing burger from Covid news. I honestly mean that.
I want to believe that this is the start of Pfizer taking over Amarin, but to play devil's advocate, could this really just be a case of Pfizer Canada operating completely independent of Pfizer Mothership and needing another drug in the Pfizer Canada bag?
Gosh, I sure doubt it, but again don't know how closely the two make these types of calls.
"HLS and Pfizer didn't make this deal without Amarin being included in the conversation."
Correct. This is the first real nibble we've had, aside from rumors right after R-It. Canada's market is microscopic for Pfizer for a co-promote arrangement like this. This isn't about Canada at all.
Everyone gets an award? Lol, that list…..
Agreed. The biggest issue of these flat sales are that any potential BP is going to be gunshy about projected V growth. We’ve squandered our “launchpad” moment, and are still at a period in time when we should be scooping up “low hanging fruit scripts” easily. We’re not doing that with 800 sales people - that’s troublesome. The $30/share dreams were dead with Du. Take a look at Lipitor’s growth before their BO.
Sign me up for $15!
Thanks for sharing. This is the failure of Amarin. Fenofibrates have now gotten more press than Vascepa re: CV19 and we’re 18 months into the pandemic.
There’s just no urgency.
Another 40,000 NBA dancer hours.....
That's interesting that he thinks it could be worse than the original ruling. I've read the opposite from other legal minds, but good to hear his take!
Agreed, but that is a different set of facts. Look, the GSK/Teva case is a nice incremental move and an important shift, but certainly doesn't 100% seal things up.
Does it shift the risk/reward for generics with respect to Vascepa, which is expensive and difficult to mfg? I certainly think yes.
Agreed. The ROI on on their marketing spend is downright embarrassing. Imagine what Mr. Wonderful or Cuban would say about their customer acquisition cost.
Right, but similarly, other insurers could just be more careful, right?
To play devil's advocate, won't the generics just be "more careful" going forward to clearly label the indication that it's meant for and the pharmacies will continue to be the infringers?
How come Algobotnews on Twitter is the only one that has mentioned anything on this? That and Teva stock up make me skeptical.
Odd that Teva stock is up.
Yeah, not sure, but seems odd to not even reference the event at the end of the month.
No. I'm fairly convinced (60%) that the results will be positive. There's enough anecdotal evidence out there + results we've already seen + the 3 ICU severe-CV19 patient data (late 2020) to draw that conclusion. My real hesitation is that the results are positive, but that Amarin (once again) fails to market/partner with the correct bodies to be successful because they think they can handle everything in-house.
I veered from the inventory question there, sorry about that.
I would agree with this anecdotal evidence. Have been on V for 2 years, and have maybe had a small cold once or twice, nothing even close to severe. Additionally, my wife has lupus and went off V for 2 weeks earlier this summer and severe joint pain returned.
Yes, agree with all of that. However, if V is truly a candidate to help with Covid, a large inventory ramp up would be required well ahead of any "launch". I'm sure they have "whisper results" at this point.
The first clue that we may be on to something will come tomorrow if there’s any mention of a ramp up of supply/inventory. Obviously CVD script growth wouldn’t be the cause for that.
How come an authorized generic isn’t worth anything in the US?
Boy, these docs are tough sells if NBA dancers are having a hard time peddling this stuff.
Unpopular opinion. AMRN should have strategically signed Steve Nissen as a high paid advisor to the company immediately after the STRENGTH failure.
I’m not short, just pissed. If we’re all around talking Amarin in 10 years, something will have gone 10x worse than the Du disaster.
40,000 mother effing hours. What is the sales team doing with 40k hours. That’s a ton of time dedicated to one drug, no others.
What the serious fu@k…..
For those that attended California schools, that's the equivalent of locking 20 people in a room for the entire work year and giving them just one task - sell Vascepa!! That's it!!
40 mother effing thousand hours. Don’t let us down AMRN sales (S)heroes!!
How does everyone in the world come up with $20k so easily? Seriously, I check Twitter and all of the super cool FinTwitters are adding to their positions $20k at a time on dips. Here on the AMRN board, it's like 5k shares added, no biggie. I make decent money, but damn, coming up with $20k of free cash to chuck at stocks takes me a LONG time.
Anyone else feel like this or are you all part of the $20k of cash every month crowd?
Not a bad batch (bottle), but maybe a few bad pills that stink up the bottle. Given I've been on V for almost 3 years, I'm very comfortable with the quality, but hard to control storage during distribution.
Nice to see all of the pandemic pent up Vascepa demand coming thru. We’re really outpacing generics as Thero mentioned.
Meanwhile Yee’s response is playing over and over in my head…..”Wow….Okay”
Thanks Raf. Let's just all just keep our expectations in check. 40,000 hours is only the equivalent of locking 20 people in a room and telling them to sell V non-stop, every working day of the year, 9-5, nothing else, no other drugs, just V.
Given the above. Flat 2021 sales make a lot of sense.
The share price reflects only sales from now until a BO. That’s it. That’s why we’re at $4.38. Even if the Marine patent was still in tact, I believe we’d be under $10 with the current (zero) growth. Look at other companies that GIA, such as AUPH. They have a game changing drug, but peak out at FDA approval and it’s tough sledding and sales until a BO. Now, we’re unique with the patent fiasco, which is why we’re in the 4s instead of the 8s or 9s.
AMRN story ends with a BO in double digits, no other option, but just a painful ride and huge opportunity costs until then. Most of us are all so scarred from this ride that we irrationally hold our full position (or add to it) due to FOMO.
I have yet to see anything publicly released stating that they are below 800, which they mentioned earlier in the year. If it's not all selling time, what is it? They have one GD drug, that's it! They don't have a bag full of products like a Pfizer rep.....one drug....the coveted top of the bag, baby! 24/7 all-day everyday selling V. It's absolutely unexplainable.
It's the absolute worst. I haven't mentioned it in a few weeks, but just a reminder that we're getting 40,000 hours PER WEEK of sales activity that is amounting to exactly zero growth.
40,000 hours is the equivalent of 20 people working for an ENTIRE YEAR, selling only 1 drug. We "get" that every week. EVERY WEEK.
Beyond sick....
Wow - that's really bad. A complete waste of cash there.
Just crazy. It was better when we weren't paying a "celebrity" though. Now we're shelling out money for these pathetic Tweets that still don't mention Vascepa or further the path to sales growth. Literally just burning cash.
That new Jaws Tweet is absolutely cringeworthy. Zero Vascepa promotion for a 1 drug company. Talking about getting ripped? LoL. These guys are truly failing at every turn.
At this point it’s just fingers crossed that they truly have traction in the EU.
I don’t even know what I would have guessed happened if you told me in Dec 2019 that we would trade < $4.50 in summer 2021.
Alien invasion?
Go AMRN!!! :)-
Eight - they can’t wait 2 years. They’ll now need to accept a risk discounted offer for the US ($5 max) and hope someone values ROW at $10 - $12.
2 more years for a big “if” won’t work with EU clock ticking....
With all due respect, these clowns can’t sell V for the world’s biggest killer, 800 salesman, National TV commercial and the CVD trial of the decade.
I think you’re probably spot on with the science against Covid, Flu, etc, but it just isn’t going anywhere with Amarin at the helm. To think otherwise would be irrational at this point given what we’ve seen from management regarding execution.